SEC Company Response from Aktis Oncology, Inc. (AKTS) (CIK 0002035832) — Jan 6, 2026
Aktis Oncology, Inc. (AKTS) (CIK 0002035832)
Date: Jan. 6, 2026 · CIK: 0002035832 · Accession: 0001193125-26-004387
AI Filing Summary & Sentiment
File numbers found in text: 333-292283
Letter
Aktis Oncology, Inc.
17 Drydock Avenue, Suite 17-401
Boston, Massachusetts 02110
January 6, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-0406
Attn: Tyler Howes
Alan Campbell
Re: Aktis Oncology, Inc.
Registration Statement on Form S-1, as amended (File No. 333-292283)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aktis Oncology, Inc. (the “Company”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-292283) of the Company, originally filed with the Securities and Exchange Commission (the “Commission”) on December 19, 2025, as amended (the “Registration Statement”), be accelerated so that such Registration Statement shall become effective at 4:00 p.m., Eastern Time, on January 8, 2026, or as soon as possible thereafter.
It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Siavosh Salimi of Paul Hastings LLP, by telephone at (212) 318-6030 or by email at seosalimi@paulhastings.com, and William A. Magioncalda of Paul Hastings LLP, by telephone at (212) 318-6088 or by email at willmagioncalda@paulhastings.com. The Company hereby authorizes Messrs. Salimi or Magioncalda of Paul Hastings LLP to orally modify or withdraw this request for acceleration.
Sincerely,
AKTIS ONCOLOGY, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Aktis Oncology, Inc. 17 Drydock Avenue, Suite 17-401 Boston, Massachusetts 02110 January 6, 2026 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-0406 Attn: Tyler Howes Alan Campbell Re: Aktis Oncology, Inc. Registration Statement on Form S-1, as amended (File No. 333-292283) Request for Acceleration of Effective Date Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aktis Oncology, Inc. (the “Company”) hereby respectfully requests that the effectiveness of the Registration Statement on Form S-1 (File No. 333-292283) of the Company, originally filed with the Securities and Exchange Commission (the “Commission”) on December 19, 2025, as amended (the “Registration Statement”), be accelerated so that such Registration Statement shall become effective at 4:00 p.m., Eastern Time, on January 8, 2026, or as soon as possible thereafter. It would be appreciated if, promptly after the Registration Statement has become effective, you would so inform our outside counsel, Siavosh Salimi of Paul Hastings LLP, by telephone at (212) 318-6030 or by email at seosalimi@paulhastings.com, and William A. Magioncalda of Paul Hastings LLP, by telephone at (212) 318-6088 or by email at willmagioncalda@paulhastings.com. The Company hereby authorizes Messrs. Salimi or Magioncalda of Paul Hastings LLP to orally modify or withdraw this request for acceleration. Sincerely, AKTIS ONCOLOGY, INC. By: /s/ Matthew Roden, PhD Name: Matthew Roden, PhD Title: Chief Executive Officer cc: Siavosh Salimi, Esq. (Paul Hastings LLP) William A. Magioncalda, Esq. (Paul Hastings LLP) Deanna L. Kirkpatrick, Esq. (Davis Polk & Wardwell LLP) Yasin Keshvargar, Esq. (Davis Polk & Wardwell LLP)